SecBot SecBot
SECBOTREPLAY Home › Report › ASND

ASND · Ascendis Pharma provided a comprehensive update on its achondroplasia…

Ascendis Pharma A/S · 6-K filed Aug 6, 2026 at 11:54 ET

At the news

BULLISHIMPACT 7/10

6-K filed Aug 6, 2026 at 11:54 ET

Ascendis Pharma provided a comprehensive update on its achondroplasia programs, including Week 78 data from the COACH combination therapy trial showing durable growth at or above the 97th percentile, and Week 104 data from the ApproaCH monotherapy trial confirming durable height improvements and benefits beyond height. The filing also noted completed enrollment for the pivotal reACHin infant trial and an anticipated EU regulatory decision for TransCon CNP in Q4 2026, alongside a U.S. launch update for YUVIWEL with over 170 patient enrollments. This is a positive clinical and regulatory update that reinforces the pipeline's potential, though no new financial data or revenue figures were provided.

  • Week 78 COACH trial data: mean AGV at or above 97th percentile of average-stature children, with tripling of efficacy vs TransCon CNP monotherapy.
  • TransCon CNP-naive cohort: mean AGV 7.73 cm/year, ACH-specific height Z-score +1.29 over 78 weeks.
  • TransCon CNP-experienced cohort: mean AGV 7.67 cm/year, ACH-specific height Z-score +1.10 over 78 weeks.
  • Week 104 ApproaCH trial data confirmed durable height improvements and benefits beyond height (lower limb alignment, body proportionality).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access